For the quarter ending June 30, 2023, PETIQ ($NASDAQ:PETQ) reported total revenue of USD 314.6 million and a net income of USD 9.5 million – an increase of 24.8% and 104.5% respectively, compared to the same period one year prior.
Analysis – Petiq Intrinsic Value
GoodWhale recently conducted an analysis of PETIQ‘s financials. Our proprietary Valuation Line calculated the fair value of PETIQ share to be around $24.2. However, the stock is currently traded at $17.4, resulting in a significant undervaluation of 28.1%. This implies that investors may benefit from purchasing the stock at its current price point. In addition, PETIQ’s financials indicate that it is well-positioned to perform strongly, given its solid balance sheet and promising market prospects. Thus, GoodWhale recommends investing in PETIQ’s stock. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Petiq. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Petiq. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Petiq. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Petiq are shown below. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The pet industry is a competitive one, with many companies vying for a share of the market. PetIQ Inc is one such company, and it competes with China Health Industries Holdings Inc, Healthy Extracts Inc, and BioGaia AB, among others.
– China Health Industries Holdings Inc ($OTCPK:CHHE)
The company’s market cap is 12.19M as of 2022, a Return on Equity of -0.5%. The company focuses on the development, manufacture and sale of health products in China.
– Healthy Extracts Inc ($OTCPK:HYEX)
Healthy Extracts Inc is a company that produces and sells health supplements. The company has a market cap of 17.93M as of 2022 and a Return on Equity of -25.8%. The company’s products are designed to improve the health and well-being of its customers.
BioGaia is a Swedish pharmaceutical company that focuses on developing and commercializing probiotics. The company’s products are based on lactic acid bacteria, which are found in the human body and are known to have numerous health benefits. Probiotics are live microorganisms that, when consumed in adequate amounts, can confer a health benefit on the host. BioGaia’s products are available in over 90 countries and are sold in a variety of formats, including capsules, tablets, liquids, and powders.
BioGaia’s market cap is 8.71B as of 2022. The company has a Return on Equity of 12.29%. BioGaia’s products are based on lactic acid bacteria, which are found in the human body and are known to have numerous health benefits. Probiotics are live microorganisms that, when consumed in adequate amounts, can confer a health benefit on the host.
Investors should take note of PETIQ‘s strong financial performance in the quarter ending June 30, 2023. The company reported total revenue of USD 314.6 million, a 24.8% increase from the same period the previous year. Similarly, net income for the period was USD 9.5 million, a remarkable 104.5% increase year-on-year. Such impressive growth indicates a potentially lucrative opportunity for shareholders and could be an attractive option for those looking to diversify their portfolio.